News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.


Berlin, 15 July 2019 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the “Company”) announced today that the Reexamination and Invalidation Department of the Patent office, China National Intellectual Property Administration (CNIPA) has, today, deemed Epigenomics’ Septin9 patent in China only partially valid. It has not been recognized for the detection of hepatocellular cancer. For the detection of colorectal cancer it has been recognized to the extent the detection is based on biological samples consisting of cell lines, histological slides, biopsies, paraffin-embedded tissue, stool, colonic effluent and combinations thereof, but not for detections based on body fluids (urine, blood plasma, blood serum, whole blood, isolated blood cells, cells isolated from the blood and combinations thereof). The decision is not yet legally effective. Epigenomics will appeal.

This decision of the CNIPA has no impact on revenue estimates for 2019 as Epigenomics did not include any Chinese licensing revenue in 2019 guidance. The decision by the CNIPA in China has no impact on Epigenomics’ Septin9 patents in other parts of the world.


Epigenomics AG, Geneststraße 5, 10829 Berlin, Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, E-Mail:

Investor Relations
IR.on AG, Frederic Hilke, Tel +49 221 9140 970, E-Mail:

Forward-Looking Statements

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any expected results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.